Nanotech Drug Delivery Could Move Chronic Pain Care Past Opioids
Nanomaterials are advancing as both precise drug carriers and agents with their own analgesic properties, offering targeted relief that may reduce...

Created by Lisa M
Ohio-focused updates on high‑dose opioid therapy, policies, and specialist access
Explore the latest content tracked by Opioid Therapy Tracker
Nanomaterials are advancing as both precise drug carriers and agents with their own analgesic properties, offering targeted relief that may reduce...
Ohio AG Andy Wilson charged 18 people with $355,000 in combined Medicaid fraud, including multiple Dayton-area cases, stressing that such schemes harm...
Lawsuits against Boston Scientific and Abbott allege SCS device malfunctions caused worsening pain, numbness, shocks, and incontinence, with claims of...
Does this pilot study show THC-CBD extracts can safely lower opioid needs in endometriosis?
Promising outcomes: 27 women saw significant drops in...
What could ARA-290 mean for small-fiber neuropathy patients losing opioid access?
Experimental peptides lack the rigorous testing required for FDA-approved options like Ozempic.
National trends show growing buprenorphine availability for opioid use disorder, yet Ohio primary care providers remain reluctant to prescribe.
-...
The AMTA report pairs a literature review on massage efficacy with a commissioned economic model, but the $11.1 billion net savings claim rests almost...
New CRPS patients gain most from picking one focused path instead of reading everything at once.
High-dose opioid tolerance allowed a 65-year-old CRPS patient on 400 MME to emerge normally after laparoscopy when baseline long-acting opioids were...
Chronic pain patients endure systemic violence through insurance denials of effective medications like Lyrica and opioids, plus scapegoating tied to...
President Trump's determination accuses Canada of hosting clandestine fentanyl labs and Chinese gangs on the northern border, linking the issue to...
The 2016 CDC guideline's MME thresholds became rigid policy limits despite the agency's own warnings about their imprecision.
High-dose opioid therapy requires documenting the agent, indication, and prescriber so a management plan can be agreed in advance when assessing spinal cord stimulation eligibility.
Ensysce presented its investigational psychedelic-based CRPS program at PainWeek 2026 to 320+ specialists and joined an FDA hearing on psychedelic...
Starting April 2027, CMS will expand its ACCESS model to continue technology-supported chronic musculoskeletal pain management beyond the initial...